Targeted therapy in triple-negative metastatic breast cancer: a systematic review and meta-analysis.

The only feasible OS meta-analysis was the one derived from the studies that tested iniparib, in which results were heterogeneous and did not reach statistical significance in a random-effects model analysis. 30 Historically, clinical studies in the advanced breast cancer setting have used PFS as the primary end point, 51 but there is still controversy concerning whether it correlates with OS. 52 , 53 In general, the toxicity reported in the studies was expected and n

also in 111,027 other papers